Get started
Author

Petra Holmkvist

Observed names: P Holmkvist, P. Holmkvist
Institution: BioInvent (Sweden)
ORCID: 0000-0002-5324-5170
Observed ORCID: 0000-0002-5324-5170
OpenAlex ID: A5042180365
Intestinal cDC1 drive cross-tolerance to epithelial-derived antigen via induction of FoxP3 + CD8 + T regs
2021 · Thorsten Joeris, Cristina Gomez-Casado, et al. · Science Immunology · 61
A major population of mucosal memory CD4+ T cells, coexpressing IL-18Rα and DR3, display innate lymphocyte functionality
2014 · P Holmkvist, K Roepstorff, et al. · Mucosal Immunology · 44
PDF
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
2022 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
IL‐18Rα‐deficient CD4+ T cells induce intestinal inflammation in the CD45RBhi transfer model of colitis despite impaired innate responsiveness
2016 · Petra Holmkvist, Lieneke Pool, et al. · European Journal of Immunology · 11
PDF
725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
2020 · Linda Mårtensson, Mathilda Kovacek, et al. · Journal for ImmunoTherapy of Cancer · 9
Abstract 936: Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists
2020 · Linda Mårtensson, Kirstie Cleary, et al. · Cancer Research · 9
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter, showing promising efficacy in T cell lymphoma patients
2025 · Stefan Barta, Christiane Querfeld, et al. · Blood · 3
PDF
757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab
2023 · Kristoffer Staahl Rohrberg, Zsuzsanna Papai, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 4156: BI-1808 - a first in class ligand-blocking αTNFR2 antibody for cancer immunotherapy
2022 · Linda Mårtensson, Kirsty Cleary, et al. · Cancer Research · 3
1073TiP A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
2024 · T.C. Hernandez Guerrero, B. Doger de Spéville, et al. · Annals of Oncology · 2
PDF
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
2023 · Linda Martensson, Petra Holmkvist, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
581 Preliminary phase 1 results of clinical trial investigating BI-1910, a tumor necrosis factor receptor 2 (TNFR2) agonist, in solid tumor cancer patients
2025 · Tatiana Hernandez, Bernard Doger, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al. · Cancer Immunology Research · 1
PDF
397 | Robust Single Agent Activity of Bi‐1808, a Tumor Necrosis Factor Receptor 2 Blocker/depleter, in T Cell Lymphoma Patients
2025 · S. Barta, J. Wallin, et al. · Hematological Oncology · 1
PDF
Abstract 3567: Comprehensive preclinical studies of BT-001: An oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
2022 · Jean-Baptiste Marchand, Monika Semmrich, et al. · Cancer Research · 1
746 Vectorized Treg-depleting anti-CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
2021 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Intestinal cDC1 Drive Cross-Tolerance to Epithelial-Derived Antigen Via Induction of FoxP3+CD8+ Tregs
2020 · Thorsten Joeris, Cristina G. Casado, et al. · SSRN Electronic Journal · 1
Regulation of T cell effector functions in the intestinal mucosa
2014 · Petra Holmkvist · Lund University Publications (Lund University) · 1
PDF
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Table 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Works count: 48
Citation count: 191
H-index: 6
I10-index: 4
Year
Topic
Type